Biotech startups that raised Series B in the United Kingdom
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| Sava Technology | London | Series B | $36.0M | 2026-10-09 |
| Mironid | Glasgow | Series B | $45.9M | 2026-08-05 |
| OXCCU | Oxford | Series B | $27.9M | 2025-09-29 |
| Cyted | Cambridge | Series B | $44.0M | 2025-08-30 |
| Greywolf Therapeutics | Abingdon | Series B | $50.0M | 2024-05-23 |
| Pheon Therapeutics | London | Series B | $120.0M | 2024-05-21 |
| LabGenius | London | Series B | $44.5M | 2024-05-21 |
8 rows of the CSV in 5 of its 18 columns.
- The 72 biotech startups in the United Kingdom whose last round is Series B have raised $2.4B in total.
- 4 of them closed their most recent round in the last 12 months, $279.9M combined.
- The largest of those rounds is T-Therapeutics' $133.0M Series B, dated November 2026.
- Innovate UK is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 59 companies (82%).
- 8% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (50% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
9 of 72| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
| Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| OXCCU | OXCCU converts carbon dioxide and hydrogen into synthetic fuels, chemicals, and biodegradable plastics. | Biotech | Oxford | Series B | $27.9M | 2025-09-29 | $54.1M | IP Group, Aramco Ventures, Clean Energy Ventures +1 | 1 to 10 | 2021 |
| Cyted | Cyted uses AI and digital pathology to improve the detection and diagnosis of diseases, including cancer. | Artificial intelligence | Cambridge | Series B | $44.0M | 2025-08-30 | $83.4M | Innovate UK, MedTech Innovator, Morningside +1 | 51 to 100 | 2018 |
| Pathios Therapeutics | Pathios Therapeutics develops therapies for autoimmune diseases and cancer. | Biotech | Oxford | Series B | $25.0M | 2024-04-18 | Innovate UK, Canaan Partners, Bristol-Myers Squibb +2 | 1 to 10 | 2017 | |
| Holiferm | Holiferm develops fermentation technology that aims to deliver large economic gains. | Biotech | Manchester | Series B | $23.2M | 2023-12-06 | Clean Growth Fund, Greater Manchester Combined Authority, ICOS Capital Management +1 | 51 to 100 | 2018 | |
| Arctic Shores | Arctic Shores provides behavior-based assessments to employers and companies. | Artificial intelligence | Manchester | Series B | $7.0M | 2023-01-16 | Beringea, Praetura Ventures, Calculus Capital +1 | 51 to 100 | 2013 | |
| ONI | ONI makes super-resolution microscopy accessible to new generations of researchers. | Biotech | Oxford | Series B | $75.0M | 2021-12-24 | $109.4M | Puhua Capital, Future Planet Capital, Oxford Science Enterprises +2 | 101 to 250 | 2016 |
Table 1. Biotech startups that raised Series B in the United Kingdom: the 9 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 72.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 2 | Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| 3 | Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
Table 2. Biotech startups that raised Series B in the United Kingdom: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 4 | 6% | ||
| 2 | Sofinnova Partners | Venture capital firm | Paris, France | 2 | 3% | 2 | T-Therapeutics, Mironid |
| 3 | Oxford Science Enterprises | Venture capital firm | Oxford, United Kingdom | 2 | 3% | ||
| 4 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 2 | 3% | ||
| 5 | Brandon Capital | Private equity firm | Melbourne, Australia | 2 | 3% | ||
| 6 | University of Cambridge Enterprise | University program | Cambridge, United Kingdom | 1 | 1% | 1 | T-Therapeutics |
| 7 | Digitalis Ventures | Venture capital firm | New York, United States | 1 | 1% | 1 | T-Therapeutics |
| 8 | F-Prime | Venture capital firm | Cambridge, United States | 1 | 1% | 1 | T-Therapeutics |
| 9 | Cambridge Innovation Capital | Venture capital firm | Cambridge, United Kingdom | 1 | 1% | 1 | T-Therapeutics |
| 10 | SOSV | Venture capital firm | Princeton, United States | 1 | 1% | 1 | Sava Technology |
| 11 | Exceptional Ventures | Venture capital firm | London, United Kingdom | 1 | 1% | 1 | Sava Technology |
| 12 | Balderton Capital | Venture capital firm | London, United Kingdom | 1 | 1% | 1 | Sava Technology |
| 13 | Social Starts | Micro VC fund | San Francisco, United States | 1 | 1% | 1 | Sava Technology |
| 14 | BioGeneration Ventures | Micro VC fund | Naarden, The Netherlands | 1 | 1% | 1 | Mironid |
| 15 | European Investment Fund | Fund of funds | Luxembourg | 1 | 1% | 1 | Mironid |
Table 3. Biotech startups that raised Series B in the United Kingdom: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 59 | 82% | $2.2B |
| Software | 9 | 12% | $285.8M |
| Artificial intelligence | 6 | 8% | $176.4M |
| Hardware | 3 | 4% | $89.4M |
| Cybersecurity | 2 | 3% | $25.7M |
| Fintech | 2 | 3% | |
| Energy | 1 | 1% | $54.1M |
| Education | 1 | 1% | $284.5M |
Table 4. Biotech startups that raised Series B in the United Kingdom by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 72 | 100% | $25.1M |
Table 5. Biotech startups that raised Series B in the United Kingdom by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| London | 23 | 32% |
| Cambridge | 15 | 21% |
| Oxford | 9 | 12% |
| Manchester | 3 | 4% |
| Cardiff | 2 | 3% |
| Little Chesterford | 2 | 3% |
| Chilworth | 2 | 3% |
| Glasgow | 1 | 1% |
| Norwich | 1 | 1% |
| Abingdon | 1 | 1% |
| Southampton | 1 | 1% |
| Burntwood | 1 | 1% |
Table 6. Biotech startups that raised Series B in the United Kingdom by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 25% | $133.0M |
| October 2026 | 1 | 25% | $36.0M |
| August 2026 | 1 | 25% | $45.9M |
| July 2026 | 1 | 25% | $65.0M |
Table 7. Biotech startups that raised Series B in the United Kingdom: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 6% | $279.9M |
| 2025 | 5 | 7% | $237.4M |
| 2024 | 11 | 15% | $533.7M |
| 2023 | 8 | 11% | $182.3M |
| 2022 | 4 | 6% | $202.3M |
| 2021 | 8 | 11% | $588.8M |
Table 8. Biotech startups that raised Series B in the United Kingdom by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 1% |
| 2020 to 2022 | 5 | 7% |
| 2015 to 2019 | 30 | 42% |
| 2010 to 2014 | 16 | 23% |
| Before 2010 | 19 | 27% |
Table 9. Biotech startups that raised Series B in the United Kingdom by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 11 | 16% |
| 11 to 50 | 35 | 50% |
| 51 to 100 | 15 | 21% |
| 101 to 250 | 8 | 11% |
| 251 to 500 | 1 | 1% |
Table 10. Biotech startups that raised Series B in the United Kingdom by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in the United Kingdom. On 16 November 2026 that is 72 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 9 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 72 rows: 6 have no round amount, 0 no city and 22 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in the United Kingdom whose last round is Series B are on the list?
- 72, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 72 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.